Linch, thanks so much for your comment. I think I agree with all of it, and I was pretty confused initially, b/c I didn’t realize the transcription error.
But yes, as David notes, the transcript flipped my point: I am not arguing that any of the external costs of alt proteins clock in at anywhere near a 1 in 10 or 1 in 30 X-risk.
My point is just (as noted in # 3 of my synopsis) that they are “sufficiently high… to warrant attention from longtermists” who are in a position to advance more than one thing (e.g., working in government or philanthropy, where you can have a portfolio).
Examples:
- Government: Adding alt proteins to one’s portfolio will often be fairly easy—e.g., at OSTP or NSF or in a congressional office.
- Philanthropy: Some philanthropists will insist on giving with a focus on global health, biodiversity, or climate; where that happens, steering them toward alt proteins can make a lot of sense.
Apologies for the transcription error—fixed, as detailed in my next comment.
Linch, thanks so much for your comment. I think I agree with all of it, and I was pretty confused initially, b/c I didn’t realize the transcription error.
But yes, as David notes, the transcript flipped my point: I am not arguing that any of the external costs of alt proteins clock in at anywhere near a 1 in 10 or 1 in 30 X-risk.
My point is just (as noted in # 3 of my synopsis) that they are “sufficiently high… to warrant attention from longtermists” who are in a position to advance more than one thing (e.g., working in government or philanthropy, where you can have a portfolio).
Examples:
- Government: Adding alt proteins to one’s portfolio will often be fairly easy—e.g., at OSTP or NSF or in a congressional office.
- Philanthropy: Some philanthropists will insist on giving with a focus on global health, biodiversity, or climate; where that happens, steering them toward alt proteins can make a lot of sense.
Apologies for the transcription error—fixed, as detailed in my next comment.